Side Effects of Drugs Annual - 1st Edition - ISBN: 9780444635259, 9780444635310

Side Effects of Drugs Annual, Volume 37

1st Edition

A worldwide yearly survey of new data in adverse drug reactions

Serial Editors: Sidhartha Ray
eBook ISBN: 9780444635310
Hardcover ISBN: 9780444635259
Imprint: Elsevier
Published Date: 4th November 2015
Page Count: 692
Tax/VAT will be calculated at check-out Price includes VAT (GST)
25% off
25% off
25% off
25% off
25% off
20% off
20% off
30% off
30% off
30% off
30% off
30% off
20% off
20% off
25% off
25% off
25% off
25% off
25% off
20% off
20% off
377.00
282.75
282.75
282.75
282.75
282.75
301.60
301.60
229.00
160.30
160.30
160.30
160.30
160.30
183.20
183.20
269.00
201.75
201.75
201.75
201.75
201.75
215.20
215.20
Unavailable
Price includes VAT (GST)
× DRM-Free

Easy - Download and start reading immediately. There’s no activation process to access eBooks; all eBooks are fully searchable, and enabled for copying, pasting, and printing.

Flexible - Read on multiple operating systems and devices. Easily read eBooks on smart phones, computers, or any eBook readers, including Kindle.

Open - Buy once, receive and download all available eBook formats, including PDF, EPUB, and Mobi (for Kindle).

Institutional Access

Secure Checkout

Personal information is secured with SSL technology.

Free Shipping

Free global shipping
No minimum order.

Table of Contents

  • Preface
  • Special Reviews in SEDA 37
  • Table of Essays, Annuals 1–36
  • Abbreviations
  • ADRs, ADEs and SEDs: A Bird's Eye View
    • I Introduction
    • References on Adverse Drug Reactions
    • II Pharmacogenomics Considerations
    • References Pharmacogenomics Considerations
    • III Immunological Reactions
    • References
    • IV Analysis of Toxicological Reactions
    • References
    • V Grades of Adverse Drug Reactions
    • References
    • VI FDA Pregnancy Categories/Classification of teratogenicity
    • References
    • Conclusion
  • Chapter 1: Central Nervous System Stimulants and Drugs That Suppress Appetite
    • Abstract
    • Methylxanthines
    • Vigilance Promoting Drugs
    • Parasympathomimetics [SEDA-32, 19; SEDA-33, 15; SEDA-34, 9]
  • Chapter 2: Antidepressants
    • Abstract
    • General
    • Selective Serotonin Re-Uptake Inhibitors (SSRIs) [SED-15, 3109; SEDA-31, 18; SEDA-32, 33; SEDA-33, 26; SEDA-34, 17; SEDA-35, 30; SEDA-36, 14]
    • Serotonin and Noradrenaline Re-Uptake Inhibitors (SNRIs)
    • Other Antidepressants
  • Chapter 3: Lithium
    • Abstract
    • Introduction
    • Organs and Systems
    • Second-Generation Effects
    • Susceptibility Factors
    • Interactions
    • Diagnosis of Adverse Drug Reactions
    • Management of Adverse Drug Reactions
    • Pharmacogenomics
  • Chapter 4: Drugs of Abuse
    • Abstract
    • Introduction
    • Cannabinoid
    • Alcohol
    • Benzodiazepines
    • Sympathomimetics—Cocaine
    • Opioids—Heroin
    • Electronic Cigarettes (E-Cigarettes)
    • Conclusion
  • Chapter 5: Hypnosedatives and Anxiolytics
    • Abstract
    • Benzodiazepines
    • Hypnosedatives and Benzodiazepine-Like Drugs
  • Chapter 6: Antipsychotic Drugs
    • Abstract
    • General [SEDA-15, 2438; SEDA-32, 83; SEDA-33, 89; SEDA-34, 51; SEDA-35, 85; SEDA-36, 59]
    • Individual Drugs
    • Acknowledgements
  • Chapter 7: Antiepileptics
    • Abstract
  • Chapter 8: Opioid Analgesics and Narcotic Antagonists
    • Abstract
    • Opioid Receptor Agonists
    • Alfentanil [SED-15, 72; SEDA-34, 152; SEDA-35, 173; SEDA-36, 108]
    • Codeine [SED-15, 880; SEDA -34, 152; SEDA-35, 174; SEDA-36, 108]
    • Dextrometrophan [SED-15, 1088; SEDA-34, 153; SEDA-35, 174; SEDA-36, 108]
    • Diamorphine [SED-15, 1096; SEDA-34, 153; SEDA-35, 175; SEDA-36, 108]
    • Dihydrocodeine [SED-15, 1125; SEDA-34, 154; SEDA-35, 175; SEDA-36, 108]
    • Fentanyl [SED-15, 1346; SEDA-34, 154; SEDA-35, 176; SEDA-36, 109]
    • Hydrocodone [SED-15, 1702; SEDA-34, 156; SEDA-35, 177; SEDA-36, 109]
    • Methadone [SED-15, 2270; SEDA-34, 157; SEDA-35, 177; SEDA-36, 110]
    • Morphine [SED-15, 2386; SEDA-34, 159; SEDA-35, 181; SEDA-36, 111]
    • Oxycodone [SED-15, 2651; SEDA-34, 161; SEDA-35, 182; SEDA-36, 111]
    • Papaverine [SED-15, 2678; SEDA-34, 162; SEDA-35, 183; SEDA-36, 112]
    • Pethidine (Meperidine) [SED-15, 2791; SEDA-34, 163; SEDA-35, 183; SEDA-36, 112]
    • Remifentanyl [SED-15, 3030; SEDA-34, 163; SEDA-35, 184; SEDA-36, 112]
    • Tramadol [SED-15, 3469; SEDA-34, 165; SEDA-35, 184; SEDA-36, 112]
    • Partial Opioid Receptor Agonists
    • Opioid Receptor Antagonists
    • Naloxone [SED-15, 2421; SEDA-35, 186; SEDA-36, 114]
    • Naltrexone [SED-15, 2423; SEDA-34, 168; SEDA-35, 186; SEDA-36, 114]
  • Chapter 9: Anti-Inflammatory and Antipyretic Analgesics and Drugs Used in Gout
    • Abstract
    • Amidopyrine and Related Compounds [SEDA-34, 184; SEDA-35, 197]
    • Aniline Derivatives [SED-15, 2679; SEDA-34, 184; SEDA-35, 197]
    • Arylalkanoic Acid Derivatives [SED-15, 2555; SEDA-34, 185; SEDA-35, 200; SEDA-36, 119–120]
    • COX-2 Selective Inhibitors [SEDA-34, 186; SEDA-35, 201; SEDA 36, 120]
    • Indoleacetic Acids [SEDA-34, 187]
    • Oxicams [SEDA-34, 187; SEDA-35, 201; SEDA-36, 126]
    • Propionic Acid Derivatives [SEDA-36, 127]
    • Salicylates [SED-15, 15; SEDA-34, 188; SEDA-35, 202; SEDA-36, 127]
    • Miscellaneous Drugs
    • Drugs Used in the Treatment of Gout
  • Chapter 10: General Anaesthetics and Therapeutic Gases
    • Abstract
    • Introduction
  • Chapter 11: Local Anesthetics
    • Abstract
    • General Information
    • Combined Anesthetics
    • Benzocaine
    • Bupivacaine
    • EMLA
    • Levobupivacaine
    • Lidocaine
    • Oxybuprocaine
    • Ropivacaine
  • Chapter 12: Neuromuscular Blocking Agents and Skeletal Muscle Relaxants
    • Abstract
    • Depolarizing Neuromuscular Blocking Agents
    • Non-Depolarizing Neuromuscular Blockers
    • Neuromuscular Blockers: Reversal Agents
    • Skeletal Muscle Relaxants
  • Chapter 13: Drugs that Affect Autonomic Functions or the Extrapyramidal System
    • Abstract
    • Drugs that Stimulate Both Alpha- and Beta-Adrenoceptors [SEDA-33, 313; SEDA-34, 233; SEDA-35, 255; SEDA-36, 179]
    • Drugs that Predominantly Stimulate Alpha 1-Adrenoceptors [SEDA-33, 318; SEDA-34, 236; SEDA-35, 257; SEDA-36, 186]
    • Drugs that Stimulate β1-Adrenoceptors [SEDA-33, 265; SEDA-34, 285; SEDA-35, 257; SEDA-36, 187]
    • Drugs that Stimulate β2-Adrenoceptors
    • Drugs that Stimulate Dopamine Receptors [SEDA-33, 266; SEDA-34, 283; SEDA-35, 262; SEDA-36, 190]
    • Drugs that Affect the Cholinergic System [SEDA-31, 272; SEDA-32, 290; SEDA-33, 324; SEDA-34, 290-1, 318; SEDA-35, 266; SEDA-36, 199]
  • Chapter 14: Dermatological Drugs, Topical Agents, and Cosmetics
    • Abstract
    • Introduction
    • Acne
    • Antifungals
    • Hair Loss Treatment
    • Pigmentation Disorders
    • Psoriasis
    • Cutaneous Side Effects from Antiviral Medications
    • Cutaneous Side Effects from Cancer Medications
    • Cutaneous Side Effects from Neurological Medications
    • Individual Medications
  • Chapter 15: Antihistamines (H1 Receptor Antagonists)
    • Abstract
    • General
    • Special Review on Pharmacogenetics
    • Other Antihistamines
  • Chapter 16: Drugs that Act on the Respiratory Tract
    • Abstract
    • Susceptibility Factors
    • Interactions
    • Long Acting Beta2-Adrenoceptor Agonists [SEDA-32, 314; SEDA-33, 357; SEDA-34, 280; SEDA 35, 315; SEDA-36, 245]
    • Interactions
    • Phosphodiesterase Inhibitors [SEDA-32, 321; SEDA-33, 367; SEDA-34, 284; SEDA-35, 321; SEDA-36, 252]
  • Chapter 17: Positive Inotropic Drugs and Drugs Used in Dysrhythmias
    • Abstract
    • Cardiac Glycosides [SED-15, 648; SEDA-34, 287; SEDA-35, 327; SEDA-36, 257]
    • Special Review—Digoxin Use and Mortality in Atrial Fibrillation
    • Other Positive Inotropes
    • Antidysrhythmic Drugs
  • Chapter 18: Beta-Adrenoceptor Antagonists and Antianginal Drugs
    • Abstract
    • Beta-Adrenoceptor Antagonists [SED-15, 452; SEDA-32, 363; SEDA-33, 397; SEDA-34, 303; SEDA-35, 351; SEDA-36, 267]
    • Interactions
    • Long-Term Effects
    • Potassium Channel Activators
    • Calcium Channel Blockers [SED-15, 598; SEDA-32, 366; SEDA-33, 401; SEDA-34, 306; SEDA-35, 354; SEDA-36, 270]
  • Chapter 19: Drugs Acting on the Cerebral and Peripheral Circulations
    • Abstract
    • Drugs Used in the Treatment of Arterial Disorders of the Brain and Limbs and in the Treatment of Migraine
    • Second Generation Effects
    • Drugs Used in the Treatment of Venous Disorders
    • Other Peripheral Vasodilators
  • Chapter 20: Antihypertensive Drugs
    • Abstract
    • Angiotensin-Converting Enzyme Inhibitors [SED-15, 226; SEDA-33, 416;SEDA-34, 321; SEDA-35,364, SEDA-36, 282]
    • Angiotensin Receptor Blockers/Angiotensin II Receptor Antagonists [SEDA-15, 2071; SEDA-34, 324; SEDA-35; SEDA-36, 282]
    • Calcium Channel Blockers
    • Direct Renin Inhibitors [SEDA-33, 420; SEDA-34, 328; SEDA-35, 373; SEDA-36, 283]
    • Direct Vasodilators [SEDA-36, 284]
    • Dopamine Beta-Hydroxylase Inhibitor
    • Drugs That Act on the Sympathetic Nervous System [SEDA-33, 424; SEDA-34, 329; SEDA-35, 376; SEDA-36, 286]
    • Diuretics
    • Endothelian Receptor Antagonists
    • Prostacyclin Analog
    • Pulmonary Vasodilators [SEDA-33, 421; SEDA-34, 328; SEDA-35, 374; SEDA-36, 284]
    • Antihypertensives in Pregnancy
  • Chapter 21: Diuretics
    • Abstract
    • Carbonic Anhydrase Inhibitors [SEDA-15, 643; SEDA-34, 339; SEDA-35, 387, SEDA-36, 289]
    • Loop Diuretics [SEDA-15, 567, 1454; SEDA-34, 342; SEDA- 35, 390; SEDA-36, 290]
    • Thiazide and Thiazide-Like Diuretics [SEDA-15, 3375; SEDA-34, 340; SEDA-35, 388; SEDA-36, 292]
    • Aldosterone Receptor Antagonists
    • Osmotic Diuretics
  • Chapter 22: Metals
    • Abstract
    • Aluminium [SED-15, 97; SEDA-32, 413; SEDA-33, 447; SEDA-34, 349; SEDA-35, 397; SEDA-36, 297]
    • Arsenic [SED-15, 339; SEDA-32, 414; SEDA-33, 448; SEDA-34, 351; SEDA-35, 399; SEDA-36, 298]
    • Antimony and Antimonials [SED-15, 316; SEDA-32, 414; SEDA-33, 448; SEDA-34, 350; SEDA-35, 398; SEDA-36, 298]
    • Beryllium [SEDA-34, 353; SEDA-35, 400; SEDA-36, 301]
    • Calcium Salts [SED-15, 610; SEDA-33, 449; SEDA-34, 354; SEDA-35, 400; SEDA-36, 301]
    • Chromium [SED-15, 737; SEDA-32, 414; SEDA-33, 450; SEDA-34, 354; SEDA-35, 401; SEDA-36, 303]
    • Cobalt [SED-15, 847; SEDA-32, 415; SEDA-33, 450; SEDA-34, 354; SEDA-35, 402; SEDA-36, 303]
    • Copper [SED-15, 901; SEDA-32, 415; SEDA-33, 450; SEDA-34, 355; SEDA-35, 402; SEDA-36, 304]
    • Gold and Gold Salts [SED-15, 1520; SEDA-32, 416; SEDA-33, 451; SEDA-34, 355; SEDA-35, 402; SEDA-36, 305]
    • Lanthanum Carbonate [SEDA-32, 417; SEDA-33, 451; SEDA-34, 356; SEDA-35, 404; SEDA-36, 306]
    • Lead [SED-15, 2013; SEDA-28, 247; SEDA-35, 404; SEDA-36, 307]
    • Iron Salts [SED-15, 1911; SEDA-32, 417; SEDA-33, 451; SEDA-34, 355; SEDA-35, 402; SEDA-36, 305]
    • Magnesium Salts [SED-15, 2196; SEDA-32, 417; SEDA-33, 452; SEDA-34, 356; SEDA-35, 406; SEDA-36, 309]
    • Mercury and Mercurial Salts [SED-15, 2259; SEDA-32, 419; SEDA-33, 453; SEDA-34, 358; SEDA-35, 407; SEDA-36, 311]
    • Nickel [SED-15, 2502; SEDA-32, 419; SEDA-33, 453; SEDA-34, 358; SEDA-35, 409; SEDA-36, 313]
    • Potassium Salts [SED-15, 2905; SEDA-31, 392; SEDA-35, 409; SEDA-36, 314]
    • Strontium Salts [SEDA-32, 420; SEDA-33, 455; SEDA-34, 359; SEDA-35, 410; SEDA-36, 315]
    • Silver Salts and Derivatives [SED-15, 3140; SEDA-32, 420; SEDA-33, 454; SEDA-34, 359; SEDA-35, 409; SEDA-36, 314]
    • Titanium [SED-15, 3434; SEDA-32, 420; SEDA-33, 456; SEDA-34, 360; SEDA-35, 410; SEDA-36, 315]
    • Zinc [SED-15, 3717; SEDA-32, 420; SEDA-33, 458; SEDA-34, 360; SEDA-35, 410; SEDA-36, 315]
  • Chapter 23: Metal Antagonists
    • Abstract
    • Introduction
    • Deferasirox [SEDA-32, 426; SEDA-33, 466; SEDA-34, 368; SEDA-35, 420; SEDA-36, 323]
    • Deferiprone [SEDA-15, 1054; SEDA-32, 427; SEDA-33, 468; SEDA-34, 370; SEDA-35, 422, SEDA-36, 327]
    • Deferoxamine/Desferrioxamine [SEDA-15, 1058; SEDA-32, 429; SEDA-33, 471; SEDA-34, 371, SEDA-35, 423]
    • Edetic Acid (EDTA) [SED-15, 1300; SEDA-31, 405; SEDA-32, 431; SEDA-33, 474; SEDA-35, 372]
    • HQK-1001 (2,2-Dimethylbutyrate)
    • Hydroxyurea [SEDA-36, 330]
    • d-Penicillamine [SEDA-15, 2729; SEDA-32, 430; SEDA-33, 472; SEDA-34, 372; SEDA-35, 424; SEDA-36, 330]
    • Trientine (Triethylenetetramine) [SEDA-15, 3508; SEDA-32, 431, SEDA-33, 474; SEDA-34, 373; SEDA-35, 427; SEDA-36, 333]
    • Tiopronin [SED-15, 3430; SEDA-35, 373]
    • Polystyrene Sulphonates [SEDA-15, 2894; SEDA-32, 433; SEDA-33, 474; SEDA-34, 373; SEDA-35, 427; SEDA-36, 333]
  • Chapter 24: Antiseptic Drugs and Disinfectants
    • Abstract
    • All Commonly Used Antiseptics and Disinfectants
    • Aldehydes [SED-15, 1439, 1513; SEDA-31, 409; SEDA-32, 437; SEDA-33, 479; SEDA-34, 377; SEDA-36, 339]
    • Guanidines
    • Benzalkonium Compounds [SED-15, 421; SEDA-32, 440; SEDA-33, 481; SEDA-34, 379; SEDA-36, 341]
    • Ethylene Oxide [SED-15, 1296; SEDA-29, 242; SEDA-34, 379; SEDA-36, 341]
    • Triclosan [SEDA-34, 379, SEDA-36, 342]
    • Halogens
    • Iodophors [SED-15, 1896; SEDA-31, 411; SEDA-32, 440; SEDA-33, 485; SEDA-34, 380; SEDA-36, 342]
  • Chapter 25: Beta-Lactams and Tetracyclines
    • Abstract
    • Carbapenems
    • Cephalosporins
    • Monobactams
    • Penicillins
    • Tetracyclines and Glycylcyclines
  • Chapter 26: Miscellaneous Antibacterial Drugs
    • Abstract
    • Aminoglycosides [SED-15, 118; SEDA-32, 461; SEDA-33, 509; SEDA-34, 399; SEDA 35, 463; SEDA-36, 363]
    • Fluoroquinolones [SEDA-15, 1396; SEDA-32, 464; SEDA-33, 514; SEDA-34, 401; SEDA-36, 464; SEDA-36, 365]
    • Glycopeptides [SEDA-32, 469; SEDA-33, 519; SEDA-34, 405; SEDA-35, 466, SEDA-36, 368]
    • Ketolides [SED-15, 1976; SEDA-32, 471; SEDA-33, 521; SEDA-34, 407; SEDA-35, 469; SEDA-36, 370]
    • Lincosamides [SED-15, 2063; SEDA-32, 472; SEDA-33, 522; SEDA-34, 407; SEDA-35, 469; SEDA-36, 371]
    • Macrolides [SED-15, 2183; SEDA-32, 472; SEDA-33, 522; SEDA-34, 408; SEDA-35, 469; SEDA-36, 371]
    • Oxazolidinones [SED-15, 2645; SEDA-32, 474; SEDA-33, 525; SEDA-34, 409; SEDA-35, 471; SEDA-36, 373]
    • Polymyxins [SED-15, 2891; SEDA-32, 476; SEDA-33, 527; SEDA-34, 412; SEDA-35, 473; SEDA-36, 374]
    • Streptogramins [SED-15, 3182; SEDA-32, 528; SEDA-34, 413; SEDA-35, 473; SEDA-36, 375]
    • Trimethoprim and Co-Trimoxazole [SED-15, 3216, 3510; SEDA-32, 477; SEDA-33, 528; SEDA-34, 414; SEDA-35, 474; SEDA-36, 375]
    • Other Antimicrobial Drugs
  • Chapter 27: Antifungal Drugs
    • Abstract
    • Allylamines [SEDA-34, 427; SEDA-35,483; SEDA-36, 381]
    • Amphotericin [SEDA-33, 542; SEDA-34, 427; SEDA-35,483; SEDA-36, 382]
    • Antifungal Azoles [SEDA-33, 545; SEDA-34, 428; SEDA-35, 484; SEDA-36, 382]
    • Pyrimadine Analogues [SEDA-36, 383]
    • Echinocandins [SEDA-33,556; SEDA-34,434; SEDA-35,489; SEDA-36, 388]
    • Anidulafungin [SEDA-35,489; SEDA-36, 388]
    • Caspofungin [SEDA-33, 556; SEDA-34, 434; SEDA-35,490; SEDA-36, 389]
  • Chapter 28: Antiprotozoal Drugs
    • Abstract
    • Introduction
    • Albendazole
    • Artemether–Lumefantrine
    • Dihydroartemisinin–Piperaquine
    • Fexinidazole
    • Fumagillin
    • Nitazoxanide
    • Oxantel Pamoate–Albendazole
    • Posaconazole
    • Primaquine
    • Quinacrine
    • Tafenoquine–Chloroquine
    • Thiamine Hydrochloride
    • Trimethoprim–Sulfamethoxazole
    • Artesunate
    • Mefloquine
    • Acetazolamide
  • Chapter 29: Antiviral Drugs
    • Abstract
    • Drugs Active Against Cytomegalovirus
    • Drugs Active Against Herpes Viruses [SEDA-32, 530; SEDA-33, 577; SEDA-34, 450, SEDA-35, 507, SEDA-36, 407]
    • Drugs Active Against Hepatitis Viruses
    • Direct-Acting Antiviral Protease Inhibitors [SEDA-35, 508; SEDA-36, 409]
    • Drugs Active Against Human Immunodeficiency Virus: Combinations
    • Drugs Active Against Human Immunodeficiency Virus: Nucleoside Analogue Reverse Transcriptase Inhibitors (NRTI) [SED-15, 2586; SEDA-32, 534; SEDA-33, 585; SEDA-34, 456; SEDA-35, 516; SEDA-36, 415]
    • Drugs Active Against Human Immunodeficiency Virus: Nucleotide Analogue Reverse Transcriptase Inhibitors
    • Drugs Active Against Human Immunodeficiency Virus: Non-nucleoside Reverse Transcriptase Inhibitors (NNRTI) [SED-15, 2553; SEDA-31, 486; SEDA-32, 537; SEDA-33, 590; SED-34, 459; SEDA-35, 519; SEDA-36, 420]
    • Drugs Active Against Human Immunodeficiency Virus: Protease Inhibitors [SED-15, 2586; SEDA-32, 541; SEDA-33, 593; SEDA-34, 461, SEDA-35, 522; SEDA-36, 423]
    • Drugs Active Against Human Immunodeficiency Virus: Inhibitors of HIV Fusion [SEDA-33; 598; SEDA-34, 464; SEDA-35, 525; SEDA-36, 428]
    • Drugs Active Against Human Immunodeficiency Virus: Chemokine Receptor CCR5 Antagonists [SEDA-33, 600; SEDA 34, 465; SEDA-35, 528; SEDA-36, 430]
    • Drugs Active Against Influenza Viruses: Ion Channel Inhibitors [SED-15, 105, 3051; SEDA-32, 544; SEDA-33, 269, 602; SEDA-34, 467; SEDA-35, 529; SEDA-36, 430]
    • Drugs Active Against Influenza Viruses: Neuraminidase Inhibitors [SED-15, 2436; SEDA-32, 544; SEDA-33, 601; SEDA-34, 466; SEDA-35, 528; SEDA-36, 431]
    • Other Drugs
  • Chapter 30: Drugs Used in Tuberculosis and Leprosy
    • Abstract
    • Rifamycins
    • Bedaquiline
    • Linezolid
    • Isoniazid
    • Ethambutol
    • Fluoroquinolones
    • Pyrazinamide
    • Clofazimine
    • Cycloserine
    • Delamanid
    • Dapsone
    • Streptomycin
  • Chapter 31: Antihelminthic Drugs
    • Abstract
    • Albendazole (SEDA-31, 508; SEDA-32, 572; SEDA-33, 647; SEDA-36, 458)
    • Ivermectin (SEDA-31, 509; SEDA-32, 575; SEDA-33, 649; SEDA-36, 460)
    • Levamisole (SEDA-31, 510; SEDA-32, 575; SEDA-33, 649; SEDA-36, 460)
    • Mebendazole (SEDA-36, 461)
    • Praziquantel (SEDA-31, 511; SEDA-33, 650; SEDA-36, 461)
    • Tribendimidine (SEDA 36, 462)
  • Chapter 32: Vaccines
    • Abstract
    • General [SEDA-36, 465]
    • Viral Vaccines
    • Bacterial Vaccines
  • Chapter 33: Blood, Blood Components, Plasma, and Plasma Products
    • Abstract
    • Albumin and Derivatives [SEDA-15, 54; SEDA-33, 670; SEDA-34, 509; SEDA-35, 583;SEDA-36, 483]
    • Blood Transfusion [SEDA-15, 529; SEDA-34, 509; SEDA-35, 583, SEDA-36, 483]
    • Blood Substitutes [SEDA-33, 672; SEDA-34, 511; SEDA-35, 586; SEDA-36, 485]
    • Plasma and Plasma Products [SEDA-15, 84; SEDA-34, 512; SEDA-35, 586, SEDA-36, 486]
    • Plasma Substitutes [SEDA-33, 675; SEDA-34, 513; SEDA-35, 587; SEDA-36, 487]
    • Globulins
    • Coagulation Proteins [SEDA-15, 845; SEDA-33, 679; SEDA-34, 518; SEDA-36, 493]
    • Erythropoietin and Derivatives [SEDA-34, 520; SEDA-35, 594; SEDA-36, 494]
    • Thrombopoietin and Receptor Agonists [SEDA-15, 3409; SEDA-36-495]
    • Transmission of Infectious Agents Through Blood Donation [SEDA-34, 521; SEDA-35,596; SEDA-36, 495]
    • Stem Cells [SEDA-34, 522; SEDA-35, 597; SEDA-36, 496]
  • Chapter 34: Drugs That Affect Blood Coagulation, Fibrinolysis and Hemostasis
    • Abstract
    • Coumarin Anticoagulants [SED-15, 983; SEDA-34, 541; SEDA-35, 617; SEDA-36, 529]
    • Heparins [SED-15, 1590; SEDA-34, 543; SEDA-35, 618; SEDA-36, 530]
    • Direct Thrombin Inhibitors [SED-15, 1142; SEDA-34, 544; SEDA-35, 619; SEDA-36, 531]
    • Direct Factor XA Inhibitors [SEDA-34, 546; SEDA-35, 620; SEDA-36, 532]
    • Thrombolytic Drugs [SEDA-15, 3402; SEDA-35, 621; SEDA-36, 532]
    • Glycoprotein IIb–IIIa Inhibitors [SED-15, 2849; SEDA-33, 720; SEDA-34, 548; SEDA-35, 622]
    • P2Y12 Receptor Antagonists [SED-15, 821; SEDA-34, 548; SEDA-35, 622; SEDA-36, 533]
    • Hemostatic Agents [SEDA-34, 549; SEDA-35, 624; SEDA-36, 536]
  • Chapter 35: Gastrointestinal Drugs
    • Abstract
    • Acid-Impacting Agents
    • Anticonstipation and Prokinetic Agents
    • Antidiarrheal and Antispasmotic Agents
    • Antiemetic Agents
    • Anti-inflammatory Agents
    • Biologics
    • Steroids
  • Chapter 36: Drugs That Act on the Immune System: Cytokines and Monoclonal Antibodies
    • Abstract
    • Cytokines
    • Interferons [SEDA-32, 676; SEDA-33, 773; SEDA-34, 581; SEDA-35, 660; SEDA-36, 564]
    • Interleukins [SEDA-33, 777; SEDA-34, 771; SEDA-36, 567]
    • Monoclonal Antibodies
  • Chapter 37: Drugs that Act on the Immune System: Immunosuppressive and Immunostimulatory Drugs
    • Abstract
    • Belatacept [SEDA 34–609]
    • Cyclophosphamide [SED-15, 1025; SEDA-34, 612; SEDA-35, 700; SEDA-36, 592]
    • Special Reviews - Cyclosporine (Ciclosporin) [SED-15, 743; SEDA-34, 609; SEDA-35, 699; SEDA-36, 591]
    • Everolimus [SED-15, 1306; SEDA-34, 614; SEDA-35, 701; SEDA 36, 592]
    • Fingolimod [SEDA-34, 616; SEDA-35, 703; SEDA-36, 593]
    • Glatiramer [SEDA-34, 617; SEDA-35, 703; SEDA-36]
    • Leflunomide [SED-15, 2015; SEDA-34, 618; SEDA-35, 703; SEDA-36, 594]
    • Mycophenolic Acid [SED-15, 2402; SEDA-34, 622; SEDA-35, 704; SEDA-36, 594]
    • Sirolimus (Rapamycin) [SED-15, 3148; SEDA-34, 626; SEDA-35, 705; SEDA-36, 594]
    • Tacrolimus [SED-15, 3279; SEDA-34, 629; SEDA-35, 705; SEDA-36, 596]
    • Temsirolimus [SEDA-34, 632; SEDA-35, 707; SEDA-36, 597]
    • Thiopurines [SED-15, 377; SEDA-34, 633; SEDA-35, 709; SEDA-36, 598]
    • Voclosporin
    • Immunoenhancing Drugs
  • Chapter 38: Corticotrophins, Corticosteroids, and Prostaglandins
    • Abstract
    • Corticotrophins [SED-15, 906; SEDA-33, 841; SEDA-34, 653; SEDA-35, 719; SEDA-36, 603]
    • Systemic Glucocorticoids [SED-15, 906; SEDA-33, 841; SEDA-34, 653; SEDA-35, 719; SEDA-36, 604]
    • Prostaglandins and Analogues [SED-15, 2955; SEDA-33, 846; SEDA-34, 660; SEDA-35, 725]
  • Chapter 39: Sex Hormones and Related Compounds, Including Hormonal Contraceptives
    • Abstract
    • Estrogens [SED-15, 1253; SEDA-34, 663; SEDA-35, 731; SEDA-36, 615]
    • Hormone Replacement Therapy [SED-15, 1684, 1686, 1692; SEDA-34, 666; SEDA-35, 732; SEDA-36, 616]
    • Hormonal Contraceptives [SED-15, 1642, 1645; SEDA-34, 667; SEDA-35, 733; SEDA-36, 618]
    • Anti-Estrogens and Selective Estrogen Receptor Modulators [SEDA-34, 669; SEDA-35, 735; SEDA-36, 619]
    • Progestogens [SED-15, 2930; SEDA-34, 671; SEDA-35, 736; SEDA-36, 622]
    • Progesterone Antagonists [SEDA-34, 671; SEDA-35, 738; SEDA-36, 625]
    • Anabolic Steroids, Androgens and Related Compounds [SED-15, 216; SEDA-34, 672; SEDA-35, 738; SEDA-36, 627]
    • Antiandrogens [SEDA-34, 674; SEDA-35, 740; SEDA-36, 628]
    • Acknowledgements
  • Chapter 40: Thyroid Hormones, Iodine and Iodides, and Antithyroid Drugs
    • Abstract
    • Thyroid Hormones [SED-15, 3409; SEDA-31, 687; SEDA-32, 763; SEDA-33, 881; SEDA-34, 679; SEDA-35, 747; SEDA-36, 635]
    • Iodine and Iodides [SED-15, 1896; SEDA-32, 764; SEDA-33, 883; SEDA-34, 680; SEDA-35, 752; SEDA-36]
    • Antithyroid Drugs [SEDA-32, 765; SEDA-33, 884; SEDA-34, 681; SEDA-35, 754, SEDA-36, 638]
  • Chapter 41: Insulin, Other Hypoglycemic Drugs, and Glucagon
    • Abstract
  • Chapter 42: Miscellaneous Hormones
    • Abstract
    • Introduction
    • Calcitonin [SEDA-34, 703; SEDA-35, 789; SEDA-36, 659]
    • Gonadotropins (Gonadorelin, GnRH and Analogues) [SEDA-35, 789; SEDA-36, 660]
    • Gonadotrophin-Releasing Hormone Antagonists [SEDA-35, 790; SEDA-36, 661]
    • Special Review - Somatropin (Human Growth Hormone, hGH) [SEDA-35, 791; SEDA-36, 661]
    • Growth Hormone Receptor Antagonists [SEDA-34, 708; SEDA-35, 792; SEDA-36, 664]
    • Melatonin and Analogues [SED-15, 2245; SEDA-35, 792; SEDA-36, 664]
    • Oxytocin and Analogues [SEDA-35, 793; SEDA-36, 665]
    • Parathyroid Hormone and Analogues [SEDA-34, 711; SEDA-35, 794; SEDA-36, 661]
    • Somatostatin (Growth Hormone Release-Inhibiting Hormone) and Analogues [SED-15, 3160; SEDA-35, 794; SEDA-36, 666]
    • Octreotide and Octreotide Long-Acting Release (LAR)
    • Pasireotide
    • Vasopressin Receptor Antagonists [SEDA-34, 713; SEDA-35, 797; SEDA-36, 668]
    • Vasopressin and Analogues [SEDA-33, 915; SEDA-34, 714; SEDA-35, 798; SEDA-36, 669]
    • Terlipressin [SEDA-34, 714; SEDA-35, 798; SEDA-36, 669]
    • Vasopressin [SEDA-34, 715; SEDA-35, 798; SEDA-36, 669]
  • Chapter 43: Drugs that Affect Lipid Metabolism
    • Abstract
  • Chapter 44: Cytostatic Agents
    • Abstract
    • Introduction
    • Pyrimidine Analogues
    • Azacitidine (5-Azacitidine)
    • Cytarabine
    • Decitabine
    • Gemcitabine
    • Fluoropyrimidines
    • Fluorouracil
    • Capecitabine
    • Acknowledgement
  • Chapter 45: Radiological Contrast Agents and Radiopharmaceuticals
    • Abstract
    • Drug Interactions
    • MRI Contrast Media
    • Ultrasound Contrast Agents [SEDA-32, 855; SEDA-33, 971; SEDA-34, 758; SEDA-35, 869; SEDA-36, 703]
  • Chapter 46: Treatments Used in Complementary and Alternative Medicine
    • Abstract
    • Introduction
    • Traditional Chinese Herbal Medicine Preparations
    • Herbal Medicine
    • Green Tea Nutritional Supplements
    • Specific Plants
    • Acupuncture
    • Cupping
    • Moxibustion
    • Osteopathy
    • Tai Chi
    • Tui Na
    • Yoga
  • Chapter 47: Miscellaneous Drugs, Materials, Medical Devices and Techniques
    • Abstract
    • Long-Term Effects
    • Benzyl Alcohol (Preservative)
  • Reviewer List
  • Index of Drugs
  • Index of Drug-Drug Interactions

  • Description

    Side Effects of Drugs Annual: A Worldwide Yearly Survey of New Data in Adverse Drug Reactions was first published in 1977, and has been continually published as a yearly update to the voluminous encyclopedia Meyler's Side Effects of Drugs. Each Annual provides clinicians and medical investigators with a reliable and critical survey of new data and trends in the area of adverse drug reactions and interactions, with an international team of specialists contributing their expertise each year.

    Key Features

    • Provides a critical yearly survey of the new data and trends regarding the side effects of drugs
    • Authored and reviewed by pioneers throughout the world in the clinical and practice sciences
    • Presents an essential clinical on the side effects of drugs for practitioners and healthcare professionals

    Readership

    Pharmacologists, clinicians, pharmaceutical companies, clinical toxicologists, clinical pharmacologists and medical libraries.


    Details

    No. of pages:
    692
    Language:
    English
    Copyright:
    © Elsevier 2015
    Published:
    Imprint:
    Elsevier
    eBook ISBN:
    9780444635310
    Hardcover ISBN:
    9780444635259

    About the Serial Editors

    Sidhartha Ray Serial Editor

    Dr. Sidhartha D. Ray serves as a Professor of Pharmaceutical Sciences and was the Founding chair of that dept. at Manchester University College of Pharmacy in Fort Wayne, Indiana, USA. Prior to joining Manchester University, Dr. Ray served as Professor of Pharmaceutical Sciences for nearly 2 decades at the Arnold & Marie Schwartz College of Pharmacy and Health Sciences of Long Island University, New York. He is a teacher and a scholar, and teaches with passion such courses as mechanisms of drug action, molecular & cellular toxicology, toxic & side effects of drugs and chemicals, pathophysiology, medical microbiology and immunology. During his 31 years of academic experience in pharmacy teaching, research and service, Dr. Ray consistently maintained a rigorous research program focusing on drug & chemical induced organ toxicology, adverse drug reaction mechanisms, side effects of a number of therapeutically relevant drugs and environmentally significant stressors. Over the last two decades, Dr. Ray’s seminal discoveries have provided clear understandings on the dynamic role of apoptosis and necrosis in drug-induced organ toxicity and have influenced the development of safety measures for a stunning variety of xenobiotics, phytochemicals and nutraceuticals. He is internationally recognized as a leader in the scientific community and was one of the front runners in exploring mechanisms of drug and chemical-induced programmed and un-programmed cell death in in-vivo models. His landmark studies on the interplay of bcl-2, bcl-xl, p53, bad and bax during acetaminophen induced cell death and its prevention by grape seed proanthocyanidin extract has earned worldwide citations. His peer recognition and acknowledged service contributions are reflected by his election into multiple international professional organizations, such as the Society of Toxicology (SOT), Society of Free Radical Biology & Medicine (SFRBM), American Society of Pharmacology & Experimental Therapeutics (ASPET), American Association of Colleges of Pharmacy (AACP) and American College of Nutrition (ACN). Dr. Ray is an Associate Editor of Encyclopedia of Toxicology (3rd Ed, Elsevier, 2014), and serves on the editorial boards of multiple prestigious international journals, including ‘Archives of Toxicology’, ‘Oxidative Medicine & Cellular Longevity’, ‘Journal of Pharmaceutical Sciences and Pharmacology’, ‘Journal of Toxicological Education’ and ‘Experimental & Clinical Sciences’.

    Based on his contributions to teaching, service and scholarship to health sciences in general, Dr. Ray received multiple prestigious awards, inc. the American Academy of Clinical Toxicology’s national research award (1996), ‘Fellow of the American College of Nutrition’ honor in 1999, David Newton Award for Excellence in Teaching Pharmacy (2005), the Biennial Abraham Krasnoff Memorial Award for Lifetime Scholarly Achievement (2008), Arnold & Marie Schwartz College of Pharmacy & Health Science’s ‘Wall-of-Fame’ honor (2011), the Society of Toxicology’s ‘Undergraduate Educator of the Year’ national award (2013), and the Manchester University’s ‘Outstanding Scholar of the Year’ award (2014). He currently serves on the SOT-NIH–NLM’s joint Toxlearn Project, SOT Undergraduate Task Force (2007 – present), and has previously served on the SOT’s Education Committee (2007 – 2010). In his lifetime, Dr. Ray has mentored research to numerous PharmD, MS, MD and PhD students in a number of areas of toxicology and biomedical sciences, made seminal contributions to the fields of pharmacology, toxicology, free radical biology, anticancer mechanism, phytochemicals, nutraceuticals & dietary supplements, and molecular safety sciences. Dr. Ray loves to promote ‘Lifelong Learning’ strategies to his students and clearly models his beliefs day in and day out. Visit URL: www.sidhartharay.com/ for more details.

    Affiliations and Expertise

    Department of Pharmaceutical Sciences, College of Pharmacy, Manchester University, Fort Wayne, IN, USA